Phase I and II trials evaluating the efficacy of intratumoral injection of a genetically modified herpes simplex virus (T-VEC) in patients with advanced melanoma, and CD40 agonist antibody (CP-870,893) in patients with pancreatic cancer, have already demonstrated its feasibility against both superficial and deep-seated tumors [50,51]. The gene discussed is CD40; the disease is familial pancreatic carcinoma.